Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05597306 · ClinicalTrials.gov registry record · Phase 1

Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia

A Phase 1 study of Acute Myeloid Leukemia and Refractory Acute Myeloid Leukemia, sponsored by Terrence J Bradley, MD.

Recruiting
Registry status
Phase 1
Development phase
18
Enrollment target
1
Study location

NCT05597306: Recruiting Phase 1 study of Acute Myeloid Leukemia and Refractory Acute Myeloid Leukemia, sponsored by Terrence J Bradley, MD.

NCT05597306 is a Phase 1 study of Acute Myeloid Leukemia and Refractory Acute Myeloid Leukemia that is actively recruiting participants, run by Terrence J Bradley, MD. The registered enrollment target is 18 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05597306, a Phase 1 study of Acute Myeloid Leukemia and Refractory Acute Myeloid Leukemia, is actively recruiting participants, sponsored by Terrence J Bradley, MD.

RECRUITING
Registry status
Phase 1
Development phase
18 participants
Enrollment target
1
Study location

Study Summary

This study aims to learn about the safety, tolerability, and different dose levels' safety profiles of Venetoclax and Bomedemstat (VenBom) combination therapy in participants with relapsed or refractory acute myeloid leukemia.

Primary Outcome

Toxicity is defined as including dose limiting toxicities (DLTs), serious adverse events (SAEs) and adverse events (AEs) in study participants. Toxicity will be assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, per physician discretion.

Conditions Studied

Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia Acute Myeloid Leukemia, in Relapse

Interventions

  • DRUG Venetoclax
  • DRUG Bomedemstat

Study Locations (1)

Florida

  • University of Miami - Miami

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2022-11-19
Est. Completion 2026-11-19
Phase Phase 1
Terrence J Bradley, MD

2 total trials

What NCT05597306 shows while recruiting

NCT05597306 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (84% lower).

The record links to 3 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Venetoclax is the first listed.

NCT05597306 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT05597306 about?

NCT05597306 is a clinical study titled "Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia". This study aims to learn about the safety, tolerability, and different dose levels' safety profiles of Venetoclax and Bomedemstat (VenBom) combination therapy in participants with relapsed or refractory acute myeloid leukemia.

What is the current status of trial NCT05597306?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2022-11-19. Estimated completion is 2026-11-19.

What conditions does trial NCT05597306 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse.

What interventions are being tested in trial NCT05597306?

The interventions under investigation include: Venetoclax (DRUG), Bomedemstat (DRUG).

Who is sponsoring clinical trial NCT05597306?

This trial is sponsored by Terrence J Bradley, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05597306 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05597306's enrollment target sits among peer trials

18 259th of 306 higher than 40 of 306 other Acute Myeloid Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01245179 · 18 participants · Phase 1

    Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

  • NCT01999361 · 18 participants · NA

    Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

  • NCT02359825 · 18 participants · Phase 1

    Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function

  • NCT02870244 · 18 participants · Phase 1

    Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05597306

Source: ClinicalTrials.gov NCT05597306, the US trial registry maintained by the National Library of Medicine. NCT05597306 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.